Role of complexes formation between drugs and penetration enhancers in transdermal delivery
Само за регистроване кориснике
2008
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The use of chemical penetration enhancers (CPE) is growing due to their ability to improve drug delivery through the skin. A possible mechanism of penetration enhancement could involve the complex formation between drug and components in the pharmaceutical formulation, thus altering the physicochemical properties of the active substance. Here, modelling studies indicate that hydrocarbon and oxygen-containing terpenes (penetration enhancers) could form complexes with drugs. Satisfactory correlations have been obtained between the predicted molecular properties of enhancers and their enhancement effects. Crown Copyright
Кључне речи:
Conformational search / Small molecule-small molecule / interactions / Transdermal delivery / Penetration enhancersИзвор:
International Journal of Pharmaceutics, 2008, 363, 1-2, 40-49Издавач:
- Elsevier Science BV, Amsterdam
Финансирање / пројекти:
DOI: 10.1016/j.ijpharm.2008.06.032
ISSN: 0378-5173
PubMed: 18675333
WoS: 000260478700003
Scopus: 2-s2.0-51749091289
Институција/група
PharmacyTY - JOUR AU - Drakulić, Branko AU - Juranić, Ivan O. AU - Erić, Slavica AU - Zloh, Mire PY - 2008 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1029 AB - The use of chemical penetration enhancers (CPE) is growing due to their ability to improve drug delivery through the skin. A possible mechanism of penetration enhancement could involve the complex formation between drug and components in the pharmaceutical formulation, thus altering the physicochemical properties of the active substance. Here, modelling studies indicate that hydrocarbon and oxygen-containing terpenes (penetration enhancers) could form complexes with drugs. Satisfactory correlations have been obtained between the predicted molecular properties of enhancers and their enhancement effects. Crown Copyright PB - Elsevier Science BV, Amsterdam T2 - International Journal of Pharmaceutics T1 - Role of complexes formation between drugs and penetration enhancers in transdermal delivery VL - 363 IS - 1-2 SP - 40 EP - 49 DO - 10.1016/j.ijpharm.2008.06.032 ER -
@article{ author = "Drakulić, Branko and Juranić, Ivan O. and Erić, Slavica and Zloh, Mire", year = "2008", abstract = "The use of chemical penetration enhancers (CPE) is growing due to their ability to improve drug delivery through the skin. A possible mechanism of penetration enhancement could involve the complex formation between drug and components in the pharmaceutical formulation, thus altering the physicochemical properties of the active substance. Here, modelling studies indicate that hydrocarbon and oxygen-containing terpenes (penetration enhancers) could form complexes with drugs. Satisfactory correlations have been obtained between the predicted molecular properties of enhancers and their enhancement effects. Crown Copyright", publisher = "Elsevier Science BV, Amsterdam", journal = "International Journal of Pharmaceutics", title = "Role of complexes formation between drugs and penetration enhancers in transdermal delivery", volume = "363", number = "1-2", pages = "40-49", doi = "10.1016/j.ijpharm.2008.06.032" }
Drakulić, B., Juranić, I. O., Erić, S.,& Zloh, M.. (2008). Role of complexes formation between drugs and penetration enhancers in transdermal delivery. in International Journal of Pharmaceutics Elsevier Science BV, Amsterdam., 363(1-2), 40-49. https://doi.org/10.1016/j.ijpharm.2008.06.032
Drakulić B, Juranić IO, Erić S, Zloh M. Role of complexes formation between drugs and penetration enhancers in transdermal delivery. in International Journal of Pharmaceutics. 2008;363(1-2):40-49. doi:10.1016/j.ijpharm.2008.06.032 .
Drakulić, Branko, Juranić, Ivan O., Erić, Slavica, Zloh, Mire, "Role of complexes formation between drugs and penetration enhancers in transdermal delivery" in International Journal of Pharmaceutics, 363, no. 1-2 (2008):40-49, https://doi.org/10.1016/j.ijpharm.2008.06.032 . .